Is Compounded Semaglutide/Tirzepatide Still Legal?

For most of 2023 and 2024, compounded semaglutide and tirzepatide were everywhere — advertised by telehealth start-ups, often for a fraction of the brand price. That market existed because of a specific, temporary feature of US drug law: when an FDA-approved drug is in short supply, licensed pharmacies are allowed to make their own versions of it. Both GLP-1 shortages have now ended, and with them the legal engine that powered cheap mass-market compounding. Compounding hasn’t been banned — but the rules it runs on are far narrower in 2026, and the FDA is actively working to tighten them further.

This page is the detailed legal status. If you want a plain comparison of how to actually obtain either drug, see how to get semaglutide and how to get tirzepatide; for the underlying mechanics of who 503A and 503B pharmacies are, see the 503A vs 503B explainer.

The shortage exception — and why it mattered

Compounding “essentially a copy” of a commercially available, FDA-approved drug is normally prohibited. The big exception is the drug shortage list. While a drug sits on that list, both kinds of compounder can step in: traditional state-licensed pharmacies (503A) making patient-specific preparations, and FDA-registered outsourcing facilities (503B) producing larger batches without an individual prescription for each unit.

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were on that list from 2022 because manufacturers couldn’t keep up with demand. That listing is what made the wave of $150–$300/month compounded GLP-1s lawful. It was always conditional. The moment the FDA decided the shortage was over, the legal foundation would disappear.

What ended, and when

The shortage designations came off in stages, and the FDA gave compounders short wind-down windows rather than an overnight cutoff.

Tirzepatide was removed from the shortage list first, at the start of October 2024. After a legal fight (below), the FDA set enforcement-discretion periods that ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. After those dates, compounders generally could no longer lean on the shortage exception to make tirzepatide copies.

Semaglutide followed. The FDA declared its shortage resolved on February 21, 2025, with wind-down periods that ran out for 503A pharmacies in April 2025 and 503B facilities in May 2025.

Note: “The shortage ended” is not the same as “compounding is banned.” It means the shortage-based pathway closed. A separate, much narrower 503A route — genuine patient-specific compounding — survives, and that distinction is the whole story in 2026.

The court fights

Compounders did not accept the shortage delistings quietly. The Outsourcing Facilities Association (OFA), joined by a 503B facility, sued the FDA over the tirzepatide removal, arguing the agency acted arbitrarily and that real-world shortages persisted. The case landed in the US District Court for the Northern District of Texas.

In March 2025 the court declined to grant the compounders a preliminary injunction, and on May 7, 2025 it upheld the FDA’s decision to take tirzepatide off the shortage list, concluding the agency had acted within its authority. That ruling has been appealed toward the Fifth Circuit, so it is not the last word — but as of mid-2026 the operative legal reality is that the shortage exception for tirzepatide is closed, and the same logic applies to semaglutide.

Running alongside the regulatory fight is private enforcement. Eli Lilly in particular has sent cease-and-desist letters and pursued litigation against pharmacies, prescribers, and sellers of compounded tirzepatide. The practical effect is that even where a gray zone exists, compounders face pressure from two directions at once.

You’ll still see some telehealth marketing describe tirzepatide as “in shortage” to justify compounding. Treat that with caution: the FDA’s official position is that it is not, and a federal court has backed that position.

What’s actually still legal in 2026

Here’s the part that gets lost in headlines: patient-specific 503A compounding did not depend on the shortage list in the first place. A state-licensed pharmacy can compound a medication when an individual prescriber writes a script for an individual patient with a documented clinical reason. That pathway operates under a different part of the law and continues.

The catch is the “essentially a copy” rule. A 503A pharmacy generally may not regularly or in inordinate amounts compound something that is essentially a copy of a commercially available drug. Once Wegovy, Ozempic, Zepbound, and Mounjaro are back in normal supply, making a plain semaglutide or tirzepatide injection that mirrors them runs straight into that prohibition. So lawful 503A compounding now tends to rest on a genuine, documented patient-specific need — for example, a clinical reason a patient can’t use the approved product as formulated. Cost alone is not such a reason, and a prescriber simply preferring the cheaper compound is not the same as a medical justification.

This is why you’ll see “personalized” formulations and additive blends marketed as a way to keep compounding. Some are legitimate clinical customization; others are thinly disguised attempts to dodge the “copy” rule by adding, say, a vitamin so the product is technically “different.” The FDA has signaled it views formulation tricks skeptically, and a B-vitamin in the vial does not by itself make a copy lawful. The honest summary: narrow, defensible, patient-specific 503A compounding remains possible; mass-market “essentially a copy” compounding does not.

The April 30, 2026 proposal — the door the FDA is trying to close

The most important recent development is forward-looking. On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list of bulk drug substances that outsourcing facilities are allowed to use without a patient-specific prescription.

Why this matters: a 503B facility may compound from a bulk substance only if that substance is on the bulks list or the drug is on the shortage list. For these GLP-1s, neither condition is currently met. Formally excluding them from the bulks list would shut the 503B door even harder — and crucially, it would foreclose 503B bulk compounding even if a future shortage were declared. Alongside the proposal, the agency issued a round of warning letters to compounding operations.

It is a proposal, not a final rule. A public comment period runs through June 29, 2026, and rulemaking takes time after that. The 503A patient-specific pathway is not what this proposal targets; it is aimed squarely at large-scale 503B production. But the direction of travel is unmistakable: the FDA is methodically removing the legal mechanisms that allowed cheap, high-volume compounded GLP-1s.

If you’re currently on a compounded GLP-1

A few things are worth understanding, without alarm:

• You are not necessarily doing anything wrong. Patients don’t police compounding law; pharmacies and prescribers do. But it’s reasonable to ask your provider whether your prescription is genuinely patient-specific 503A compounding or a holdover from the expired shortage exception.
• Brand supply has recovered. The original reason many people chose compounded — you couldn’t get the brand — has largely gone away. Brand pens are stocked at major retail pharmacies, and manufacturer cash-pay programs have brought self-pay prices down (covered on the cost and direct-to-consumer pricing pages).
• Quality varies. Compounded products are not FDA-approved or batch-reviewed the way brand drugs are. Reputable 503A pharmacies follow USP standards, but the market also attracted bad actors, and the FDA has flagged dosing errors and contamination concerns with some compounded GLP-1s.
• “Research use only” vials are not a route. Material sold RUO is for laboratory use, not human injection. Buying it to self-administer leaves the prescription system entirely and carries real safety risk. See research peptides explained.

Bottom line

Compounded semaglutide and tirzepatide are not illegal in 2026, but the easy, cheap, shortage-driven version of that market is over. What remains is narrow, patient-specific 503A compounding with a documented clinical reason — a real pathway, but a much smaller one — while the FDA’s April 2026 proposal moves to close the 503B door for good. Because this is one of the fastest-moving areas in US drug regulation, treat any specific status here as current to the lastUpdated date and likely to change. If affordability is the issue, the brand cash-pay programs and insurance pathways are now the more durable place to look.